Loading…
Aligos Therapeutics, Inc. is projected to decline to $5.46 by 2027, a -3% move from its current price of $5.60. ALGS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.36 | $5.61 | $5.86 | +0.09% |
| May 30 | $5.27 | $5.61 | $5.97 | +0.18% |
| May 31 | $5.20 | $5.62 | $6.07 | +0.27% |
| Jun 1 | $5.14 | $5.62 | $6.14 | +0.36% |
| Jun 2 | $5.09 | $5.63 | $6.21 | +0.45% |
| Jun 3 | $5.05 | $5.63 | $6.28 | +0.55% |
| Jun 4 | $5.01 | $5.64 | $6.34 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.01 | $5.64 | $6.34 | +0.64% |
| Week 2 | $4.80 | $5.67 | $6.70 | +1.28% |
| Week 3 | $4.65 | $5.71 | $7.00 | +1.92% |
| Week 4 | $4.54 | $5.74 | $7.27 | +2.57% |
| Week 5 | $4.44 | $5.78 | $7.52 | +3.22% |
| Week 6 | $4.36 | $5.82 | $7.76 | +3.88% |
| Week 7 | $4.29 | $5.85 | $7.99 | +4.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate ALG-055009 is a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc.
was incorporated in 2018 and is headquartered in South San Francisco, California.
Aligos Therapeutics, Inc. (ALGS) is a healthcare stock with a current price of $5.76. It has a market cap of $35.64M and is ranked 4739 by market capitalization. The stock price outlook reflects a multi-year forecast that shows near-term neutrality through 2026–2030, followed by a shift to bullish momentum from 2031 onward.
The forecast envisions rising averages and higher price ceilings in the long term, with notable increases by 2040 and 2050.
A major floor 34.5% below — a decisive break under it would weaken the trend.
The nearest floor, 7.5% below — buyers have tended to step in here.
The nearest ceiling, 36.8% above — a clean break opens room to run.
A major ceiling 56.1% above — clearing it would confirm fresh momentum.
Key ALGS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALGS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.68 | Sell | $5.68 | Sell |
| MA 10 | $5.80 | Sell | $5.79 | Sell |
| MA 20 | $6.02 | Sell | $6.03 | Sell |
| MA 50 | $6.73 | Sell | $6.57 | Sell |
| MA 100 | $7.23 | Sell | $7.20 | Sell |
| MA 200 | $8.39 | Sell | $8.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.54 | Neutral |
| Stoch RSI (14) | 42.32 | Neutral |
| CCI (20) | -78.24 | Neutral |
| Williams %R (14) | -72.19 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -13.04 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 27.81 | Neutral |
| TRIX (15) | -0.70 | Sell |
| Awesome (5,34) | -0.80 | Sell |
| Ultimate (7,14,28) | 42.36 | Neutral |
| Momentum (10) | -0.87 | Sell |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 5.72 | Sell |
| ADX (14) | 17.37 | Neutral |
| ATR (14) | 0.24 | Info |
The current technical picture is Bearish, with RSI14 at 40. The stock trades with a SMA50 of $6.81 and a SMA200 of $8.42. The 30-day price range spans from a low of $4.22 to a high of $7.86. Support is identified at $5.18 and resistance at $8.74, framing near-term risk and reward.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.18 | $5.60 | $7.22 | 0% | Neutral | |
| $4.06 | $5.46 | $7.89 | -3% | Neutral | |
| $3.71 | $5.22 | $7.97 | -7% | Neutral | |
| $3.48 | $5.11 | $8.12 | -9% | Neutral | |
| $3.64 | $5.54 | $9.13 | -1% | Neutral | |
| $4.71 | $7.41 | $12.57 | +32% | Bullish | |
| $4.95 | $8.04 | $14.01 | +44% | Bullish | |
| $4.32 | $7.24 | $12.92 | +29% | Bullish | |
| $4.31 | $7.44 | $13.58 | +33% | Bullish | |
| $3.98 | $7.07 | $13.17 | +26% | Bullish | |
| $5.69 | $11.59 | $23.48 | +107% | Bullish | |
| $8.83 | $19.63 | $44.84 | +251% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.18 | $5.60 | $6.63 | +0.00% |
| June 2026 | $4.89 | $5.82 | $7.15 | +3.88% |
| July 2026 | $5.04 | $6.08 | $7.64 | +4.57% |
| August 2026 | $4.83 | $5.90 | $7.53 | -3.05% |
| September 2026 | $4.61 | $5.68 | $7.34 | -3.72% |
| October 2026 | $4.65 | $5.78 | $7.56 | +1.73% |
| November 2026 | $4.58 | $5.73 | $7.57 | -0.86% |
| December 2026 | $4.29 | $5.41 | $7.22 | -5.57% |
Click any year to see its month-by-month ALGS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ALGS could reach as high as $7.22, with a base case around $5.60 and support toward $5.18 — roughly 0% from $5.60. Price action looks broadly range-bound.
Expect ALGS to range from $4.06 to $7.89 through 2027. The $5.46 average target implies a -3% move from current prices. That is -3% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The ALGS price prediction for 2028 points to an average of $5.22 (low $3.71, high $7.97) — a potential decline of -7% on today's $5.60. Price action looks broadly range-bound.
In 2029, ALGS is projected to trade between $3.48 and $8.12, averaging $5.11 — a potential decline of -9% from today's $5.60. That is -2% versus the projected 2028 average. A consolidation phase looks the most probable path here.
Aligos Therapeutics, Inc.'s 2030 outlook centres on $5.54, within a $3.64 to $9.13 range. That is up +9% on the projected 2029 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2031, ALGS could reach as high as $12.57, with a base case around $7.41 and support toward $4.71 — roughly +32% from $5.60. Buyers look set to stay in control over this stretch.
Expect ALGS to range from $4.95 to $14.01 through 2032. The $8.04 average target implies a +44% move from current prices. That is up +8% on the projected 2031 average. Momentum favours further upside here.
The ALGS price prediction for 2033 points to an average of $7.24 (low $4.32, high $12.92) — a potential gain of +29% on today's $5.60. Buyers look set to stay in control over this stretch.
In 2034, ALGS is projected to trade between $4.31 and $13.58, averaging $7.44 — a potential gain of +33% from today's $5.60. That is up +3% on the projected 2033 average. Momentum favours further upside here.
Aligos Therapeutics, Inc.'s 2035 outlook centres on $7.07, within a $3.98 to $13.17 range. That is -5% versus the projected 2034 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ALGS could reach as high as $23.48, with a base case around $11.59 and support toward $5.69 — roughly +107% from $5.60. Momentum favours further upside here.
Expect ALGS to range from $8.83 to $44.84 through 2050. The $19.63 average target implies a +251% move from current prices. That is up +69% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALGS today (≈ 178.571429 ALGS) could be worth
$3,505.01
+$2,505.01 (+251%) by 2050 · US Dollar
Based on the average projected ALGS price of $19.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALGSwould be worth at today's price.
$1,000 invested in ALGS on May 27, 2025 (≈ 178.890872 ALGS) would be worth
$1,001.79
+$1.79 (+0.2%) today · 1.00× · US Dollar
Based on a ALGS entry price of $5.59 vs. today's $5.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.6 | $1,000 | +0.0% |
| 1 month ago | $6.43 | $870.92 | -12.9% |
| 3 months ago | $7.5 | $746.67 | -25.3% |
| 6 months ago | $9.58 | $584.55 | -41.5% |
| 1 year ago | $5.59 | $1,001.79 | +0.2% |
| All time (5.0y) ago | $696.5 | $8.04 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALGS forecast.
Our base-case forecast reaches $11.00 around 2040.
Implied market cap at $11.00: $59.27M
In the 2026–2030 window, the forecast shows modest near-term dynamics with min prices around the low $5s and avg prices around the mid $5s, dipping to a min of $3.36–$3.56 and a max near $9.24 in 2030, with a 2030 average of $5.52 and a ROI of -4.2. Beginning in 2031, the outlook turns bullish, with 2031 averaged at $7.36 and a max of $12.72, and a ROI of 27.7. The subsequent years 2032–2035 show continued gains, with 2032 avg $8.01, 2033 avg $7.22, 2034 avg $7.29, and 2035 avg $6.91, all with positive ROIs (39, 25.4, 26.6, and 20 respectively).
The forecast then sharpens higher in 2040 to an avg of $11.31 (ROI 96.3) and reaches an avg of $18.81 by 2050 (ROI 226.5), with bullish sentiment in those long-horizon years. These figures are estimates, not guarantees.
Tap a question to reveal the answer.
In 2030, the forecast shows a min of $3.56, an avg of $5.52, and a max of $9.24, with a ROI of -4.2 and neutral sentiment.
Near term is neutral through 2026–2030, with a shift to bullish momentum from 2031 onward. The 2031–2050 outlook shows rising averages and positive ROIs, but these are estimates, not guarantees.
Yes. The 2031 max forecast is $12.72 and the 2032 max forecast is $14.23, indicating a $10 target is within the forecasted upper bounds in 2031 and beyond.
Current price: $5.76. Market cap: $35.64M. Rank: 4739.
2040 avg price is $11.31 with a ROI of 96.3 and bullish sentiment. 2050 avg price is $18.81 with a ROI of 226.5 and bullish sentiment.
Aligos Therapeutics, Inc. Community Discussion
0Share your Aligos Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.